Circulating C-Terminal Agrin Fragment is Associated with Impaired Physical Performance in Aging and Chronic Disease: A Systematic Review and Meta-Analysis.
Key claim: Elevated circulating C-terminal agrin fragment (CAF22) concentrations are consistently associated with slower gait speed and lower SPPB scores across both healthy older adults and clinical cohorts.
Abstract
BACKGROUND: Circulating C-terminal agrin fragment (CAF22) is a biomarker of neuromuscular junction degradation and sarcopenia. However, its relationship with objective measures of physical performance has not been systematically evaluated. This systematic review and meta-analysis examined associations of circulating CAF22 concentrations with gait speed and Short Physical Performance Battery (SPPB) scores in aging and chronic disease populations. METHODS: PubMed, Scopus, Web of Science, and Google Scholar were searched to identify studies reporting associations between circulating CAF22 concentrations and gait speed and/or SPPB scores. Correlation coefficients were extracted, transformed to Fisher’s z values, and pooled using random-effects meta-analysis. Risk of bias, heterogeneity, subgroup differences, and publication bias were assessed. RESULTS: Twenty-one studies met the inclusion criteria, contributing 33 cohorts for gait speed (n = 3136) and 28 cohorts for SPPB (n = 2773). Higher circulating CAF22 concentrations were significantly associated with slower gait speed in controls (r = - 0.309, 95% CI - 0.371 to - 0.244%) and disease cohorts (r = - 0.309, 95% CI - 0.361 to - 0.254%), yielding an overall pooled correlation of r = - 0.308 (95% CI - 0.346 to - 0.269%). CAF22 concentrations were also inversely associated with SPPB scores in controls (r = - 0.335, 95% CI - 0.415 to - 0.250%) and disease cohorts (r = - 0.368, 95% CI - 0.422 to - 0.312%), with an overall pooled correlation of r = - 0.353 (95% CI - 0.397 to - 0.307%). No significant subgroup differences were detected. CONCLUSIONS: Elevated circulating CAF22 concentrations are consistently associated with poorer physical performance across healthy and chronic disease populations, supporting CAF22 as a promising biomarker of functional decline.
Why this matters
[human-observational] This synthesis connects circulating CAF22 with physical-performance measures across healthy older adults and chronic-disease cohorts, extending the evidence for a blood-based correlate of functional impairment. [human-observational] Association with current performance does not by itself establish reliable prediction of future decline, assay reproducibility, or that intervention-induced reductions represent functional recovery or de-aging.